<DOC>
	<DOCNO>NCT02191293</DOCNO>
	<brief_summary>Collecting data maintain anti-retroviral activity ( quantitative HIV RNA determination ) immunological activity ( CD4 cell ) switch protease inhibitor NNRTI Nevirapine ( Viramune® ) collect routinely observe laboratory data lipid , liver enzymes .</brief_summary>
	<brief_title>Long-term Study Patients Under Anti-retroviral Combination Therapy Switching Viramune®</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Adult male female outpatient HIV type 1 infection achieve viral load detection limit ( 50 copies/ml ) 6 month previous combination therapy proteaseinhibitors ( PI ) nonnucleoside reverse transcriptase inhibitor ( NNRTI ) Women include , test exclude pregnancy Only woman include , use reliable mean contraception observational study Known sensitivity Viramune one excipients Clinically relevant change lab finding ( e.g . increase aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) fivefold upper limit normal ) Patient able abstain treatment ketoconazole , oral contraceptive , medication CYP3A metabolism For female : Pregnancy Breastfeeding Insufficient unreliable contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>